An industrial perspective on ligand bias in GPCR drug discovery
{{output}}
Since the initial identification of ligand bias in the late 1990s, the possibility of designing new clinical compounds that preferentially target select signalling pathways has been attractive to drug developers. The potential for maximising efficacy and minim... ...
